All In Biotech

NDA 215727 · Agepha Pharma Fz

Lodoco

Colchicine · Oral · Alkaloid

Priority review

Last checked: Nov 19, 2026Latest source record: Jun 16, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Jun 16, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

313

94 Phase 3, 51 recruiting

FAERS reports

24

8 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 20, 2026.

1. INDICATION AND USAGE LODOCO is indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease. LODOCO is an alkaloid indicated: • to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease ( 1 ).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 16, 2023 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LetterLabelReview
1 products under this application
  • LODOCO · COLCHICINE 0.5MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Colchicine" as an intervention, any sponsor and status, largest first.

All 313 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea4
  • abdominal discomfort3
  • pain3
  • dizziness2
  • fatigue2
  • nausea2
  • product use in unapproved indication2
  • product use issue2
  • abdominal pain1
  • abdominal pain upper1
  • adverse event1
  • back pain1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20071
20247
20257
20269

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lodoco (Colchicine)

2024 spending

$606K

Beneficiaries

294

723 claims

Per beneficiary

$2,060

$15.74 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$45,668
2024$605,582

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 768 on PubMed

Sponsor: Agepha Pharma Fz

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.